A fractal model for erythrocyte sedimentation

Kuo, Cheng‐Deng; Bai, Jing-Jang; Chien, Shu

doi:10.3233/bir-1994-31107

Cited by 5 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the mathematical models of erythrocyte network settling, the most interesting is the fractal model [62] which describes the process by an S-shaped sedimentation curve. A distinguishing feature of this theory is its fractality.…”

Section: Dynamics Of Blood Sedimentation Rate As a Biosensormentioning

confidence: 99%

Metrological approaches to drug development. Fast screening using universal biosensors at the stage of drug development

et al. 2012

View full text Add to dashboard Cite

We expect that in the near future drug development will become the most interesting and demanded application of the suggested approach. Taking a known drug as the reference point and performing its chemical modification, one can sharply reduce the time and financial expenses for bioactivity testing of new substances and experimentally predict its general toxicity on a biological model the most adequate to human body.Development and commercialization of a new drug is a long-term and expensive process. It takes 10-20 for a biologically active substance to pass way from laboratory synthesis or isolation to application as a drug [1]. If 20 years ago this process costed slightly more than $300 mln, then now the cost may reach $1 bln. Therewith, only 3 of 5 newly commercialized drugs make a profit greater or equal to expenses on its development.One of the approaches to the problem of reduction of terms and costs of drug development involves screening of biologically active substances and drugs on their basis at the development stage. Such screening can be performed by means of biosensors.The end of XX century was marked by the advent of a new field of science-biosensing. Unfortunately, already in a few years the term "biosensors" started to be related to electronic devices, and attention started to be focused exclusively on the development of high-selectivity specific biosensors. However, with time, researchers returned to nonspecific universal bio-sensors on the basis of live systems. Biosensing as one of the components of the methodology of drug development allows fast selection of physiologically active substances as potential candidates for medical applications.

show abstract

Section: Dynamics Of Blood Sedimentation Rate As a Biosensormentioning

confidence: 99%